NCT06281405View on ClinicalTrials.gov

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2028

Conditions
Locally Advanced Rectal CancerNeoadjuvant Therapy
Interventions
DRUG

PD-1 antibody

PD-1 antibody (Toripalimab): 240mg d1 q3w

DRUG

Capecitabine

Capecitabine: 1000mg/m2 bid d1-14 q3w

RADIATION

Short-course radiotherapy

Short-course radiotherapy: 25Gy/5Fx

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06281405 - CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter